WO2004060347A3 - Compositions pharmaceutiques de solvates de propylene glycol - Google Patents

Compositions pharmaceutiques de solvates de propylene glycol Download PDF

Info

Publication number
WO2004060347A3
WO2004060347A3 PCT/US2003/041642 US0341642W WO2004060347A3 WO 2004060347 A3 WO2004060347 A3 WO 2004060347A3 US 0341642 W US0341642 W US 0341642W WO 2004060347 A3 WO2004060347 A3 WO 2004060347A3
Authority
WO
WIPO (PCT)
Prior art keywords
propylene glycol
pharmaceutical
glycol solvate
compositions
solvate compositions
Prior art date
Application number
PCT/US2003/041642
Other languages
English (en)
Other versions
WO2004060347A2 (fr
Inventor
Mark Tawa
Oern Almarsson
Julius Remenar
Original Assignee
Transform Pharmaceuticals Inc
Mark Tawa
Oern Almarsson
Julius Remenar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/232,589 external-priority patent/US6559293B1/en
Priority claimed from US10/601,092 external-priority patent/US20050025791A1/en
Priority claimed from PCT/US2003/028982 external-priority patent/WO2004026235A2/fr
Priority claimed from PCT/US2003/041273 external-priority patent/WO2004061433A1/fr
Application filed by Transform Pharmaceuticals Inc, Mark Tawa, Oern Almarsson, Julius Remenar filed Critical Transform Pharmaceuticals Inc
Priority to AU2003300452A priority Critical patent/AU2003300452A1/en
Priority to PCT/US2004/009947 priority patent/WO2004089313A2/fr
Priority to US10/551,014 priority patent/US20060223794A1/en
Publication of WO2004060347A2 publication Critical patent/WO2004060347A2/fr
Publication of WO2004060347A3 publication Critical patent/WO2004060347A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques comprenant des solvates d'API de propylène glycol.
PCT/US2003/041642 2002-02-15 2003-12-29 Compositions pharmaceutiques de solvates de propylene glycol WO2004060347A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003300452A AU2003300452A1 (en) 2002-12-30 2003-12-29 Pharmaceutical propylene glycol solvate compositions
PCT/US2004/009947 WO2004089313A2 (fr) 2003-04-01 2004-03-31 Nouvelles formes de l'olanzapine et methodes de traitement associees
US10/551,014 US20060223794A1 (en) 2002-02-15 2004-03-31 Novel olanzapine forms and related methods of treatment

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US10/232,589 US6559293B1 (en) 2002-02-15 2002-09-03 Topiramate sodium trihydrate
US43751602P 2002-12-30 2002-12-30
US60/437,516 2002-12-30
US44133503P 2003-01-21 2003-01-21
US60/441,335 2003-01-21
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
US45660803P 2003-03-21 2003-03-21
US60/456,608 2003-03-21
US45950103P 2003-04-01 2003-04-01
US60/459,501 2003-04-01
US10/601,092 2003-06-20
US10/601,092 US20050025791A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
USPCT/US03/19574 2003-06-20
PCT/US2003/019574 WO2004000284A1 (fr) 2002-06-21 2003-06-20 Compositions pharmaceutiques a dissolution amelioree
US48671303P 2003-07-11 2003-07-11
US60/486,713 2003-07-11
USPCT/US03/28982 2003-09-16
PCT/US2003/028982 WO2004026235A2 (fr) 2002-09-20 2003-09-16 Compositions pharmaceutiques presentant une dissolution amelioree
PCT/US2003/041273 WO2004061433A1 (fr) 2002-12-30 2003-12-24 Compositions pharmaceutiques a dissolution amelioree
USPCT/US03/41273 2003-12-24

Publications (2)

Publication Number Publication Date
WO2004060347A2 WO2004060347A2 (fr) 2004-07-22
WO2004060347A3 true WO2004060347A3 (fr) 2004-11-04

Family

ID=56290517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041642 WO2004060347A2 (fr) 2002-02-15 2003-12-29 Compositions pharmaceutiques de solvates de propylene glycol

Country Status (1)

Country Link
WO (1) WO2004060347A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9102758B2 (en) 2004-07-19 2015-08-11 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1515703A1 (fr) 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a dissolution amelioree
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2007070562A2 (fr) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Compositions non hygroscopiques d'enterostatine
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2570949A1 (fr) 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Solvate d'ibandronate sodique et de propyleneglycol et methodes de preparation connexes
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
WO2010002675A2 (fr) 2008-06-30 2010-01-07 Mutual Pharmaceutical Company, Inc. Complexe solide de sulfate/bisulfate de quinine; procédés de préparation; et procédés d’utilisation de celui-ci
CA2804215C (fr) 2009-07-22 2019-10-01 Eric Elenko Procedes et compositions de traitement de troubles, ceux-ci etant ameliores par l'activation du recepteur muscarinique
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US9624258B2 (en) * 2013-05-30 2017-04-18 Biophore India Pharmaceuticals Pvt. Ltd. Polymorph of regadenoson
EP3108879A1 (fr) 2015-06-25 2016-12-28 Cassiopea S.p.A. Formulation à concentration élevée
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008321A (en) * 1974-12-20 1977-02-15 Toko Yakuhin Kogyo Kabushiki Kaisha Composition for a topical preparation and a process for producing the same
JPS5495589A (en) * 1977-12-30 1979-07-28 Sumitomo Chem Co Ltd Production of cephalosporin derivative
US4853379A (en) * 1982-12-09 1989-08-01 Societe Anonyme Dite: L'oreal Stable hydrocortisone-based composition for use in local corticotherapy
WO1995023596A1 (fr) * 1994-03-05 1995-09-08 The Boots Company Plc Formulations pharmaceutiques topiques depourvues d'adhesif
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US6420394B1 (en) * 1997-04-10 2002-07-16 Roche Consumer Health (Worldwide) Sa Topically applied pharmaceutical formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008321A (en) * 1974-12-20 1977-02-15 Toko Yakuhin Kogyo Kabushiki Kaisha Composition for a topical preparation and a process for producing the same
JPS5495589A (en) * 1977-12-30 1979-07-28 Sumitomo Chem Co Ltd Production of cephalosporin derivative
US4853379A (en) * 1982-12-09 1989-08-01 Societe Anonyme Dite: L'oreal Stable hydrocortisone-based composition for use in local corticotherapy
WO1995023596A1 (fr) * 1994-03-05 1995-09-08 The Boots Company Plc Formulations pharmaceutiques topiques depourvues d'adhesif
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US6420394B1 (en) * 1997-04-10 2002-07-16 Roche Consumer Health (Worldwide) Sa Topically applied pharmaceutical formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 197936, Derwent World Patents Index; Class B02, AN 1979-65538B, XP002282989 *
FUNG H L ET AL: "Solvent effects on comparative dissolution of pharmaceutical solvates", CHEMICAL AND PHARMACEUTICAL BULLETIN 1974, vol. 22, no. 2, 1974, pages 454 - 458, XP009031785 *
RUBINO J T ET AL: "INFLUENCE OF SOLVENT COMPOSITION OF THE SOLUBILITIES AND SOLID-STATE PROPERTIES OF THE SODIUM SALTS OF SOME DRUGS", INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), vol. 65, no. 1-2, 1990, pages 141 - 145, XP002282988, ISSN: 0378-5173 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102758B2 (en) 2004-07-19 2015-08-11 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US9101596B2 (en) 2004-07-19 2015-08-11 Biocon Limited Cation complexes of insulin compound conjugates, formulations and uses thereof
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Also Published As

Publication number Publication date
WO2004060347A2 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2004060347A3 (fr) Compositions pharmaceutiques de solvates de propylene glycol
MXPA02012891A (es) Composiciones farmaceuticas de agentes estrogenicos.
MXPA05010659A (es) Formulaciones veterinarias antihelminticas topicas.
HK1076605A1 (en) Formulations
WO2001078680A3 (fr) Compositions pharmaceutiques
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2004043363A3 (fr) Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
WO2000066104A3 (fr) Composes inhibant ace-2 et leurs procedes d'utilisation
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
SG165404A1 (en) Fulvestrant formulation
EP1420787B8 (fr) Compositions ophtalmiques
HK1087399A1 (en) Pharmaceutical formulations comprising highly purebases of 3, 3-giphenylpropylamine monoesters
WO2001005355A3 (fr) Formulations d'il-11
WO2004069138A3 (fr) Formulation pharmaceutique
EP2308479A3 (fr) Composés et compositions pour la distribution d'agents actifs
WO2002015959A3 (fr) Composes et compositions permettant de distribuer des agents actifs
WO2002070464A3 (fr) Nouvelles hydrazones
WO2002094856A3 (fr) Peptidomimetiques et analogues de gpe
EP1608395A4 (fr) Agent anticancereux comprenant une proteine lk8 en tant que principe actif
WO2005065639A3 (fr) Nouvelles compositions pharmaceutiques
EP1407780A4 (fr) Compositions hemostatiques pharmaceutiquement stables
WO2004087101A3 (fr) Formulations de cladribine a administration par voie orale
WO2002085358A3 (fr) Agents antiviraux et methodes de traitement d'infections virales
WO2004047798A3 (fr) Formulations de finastéride
AU2003259986A1 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP